2022
Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.Peer-Reviewed Original ResearchConceptsDisease-specific mortalityAdvanced neoplasiaBD-IPMNsExtended surveillancePooled incidenceWorrisome featuresSystematic reviewIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmHigh-quality studiesRandom-effects modelWarrants further investigationWeb of ScienceNeoplasia incidenceWarrants further explorationSurvival benefitCochrane LibraryMucinous neoplasmsPancreatic cancerPancreatic cystsSurveillance periodEligible studiesOvid MEDLINELower incidence
2019
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan N, Ahuja N. The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers 2019, 11: 1859. PMID: 31769422, PMCID: PMC6966483, DOI: 10.3390/cancers11121859.Peer-Reviewed Original ResearchATP-dependent chromatinChromodomain helicase DNA-binding proteinStem cell maintenanceDNA-binding proteinsAberrant chromatin modificationsChromatin modificationsChromatin structureMain subfamiliesCell maintenanceEpigenetic dysregulationChromatinDifferent cancer typesSwitch/Genomic alterationsCritical roleSmall moleculesFrequent mutationsCancer typesChromosomal aberrationsEmerging RoleComplexesLower survival rateAggressive cancerPancreatic cancerMechanistic studiesPromoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, Tam M, Pisanic TR, Iacobuzio-Donahue CA, Hruban RH, He J, Wang TH, Wood LD, Sharma A, Ahuja N. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics 2019, 11: 59. PMID: 30953539, PMCID: PMC6451253, DOI: 10.1186/s13148-019-0650-0.Peer-Reviewed Original ResearchConceptsStage IIB diseasePancreatic cancerIIB diseaseStage IIACA 19Stage IBiomarker panelBlood-based biomarker panelPre-operative CA 19Stage I patientsCell-free tumor DNAHigh-risk populationPotential blood biomarkersMost pancreatic cancersBackgroundDespite improvementsCurative resectionSurgical resectionI patientsTwo-gene panelPancreas cancerBlood biomarkersCurative potentialCancer managementAdvanced stageCombination panel
2017
Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, Lennon AM, Wood LD, Hruban RH, Zheng L, Zaheer A, Fishman EK, Ahuja N, Cameron JL, Weiss MJ, He J, Wolfgang CL. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2017, 266: 339-345. PMID: 27631774, DOI: 10.1097/sla.0000000000001988.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmInvasive carcinomaPredictive nomogramLymphocyte ratioMucinous neoplasmsInvasive malignancyPredictive markerMain pancreatic duct dilatationEnhanced solid componentLymphocyte ratio valuesIndependent predictive markerFurther prospective studiesPancreatic duct dilatationInflammatory markersSurgical resectionDuct dilatationNLR valuesOverall survivalProspective studyPancreatic cancerC-indexCarcinomaMultivariate analysisPatientsLong‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiation
2015
Early detection of pancreatic cancer.
Kim VM, Ahuja N. Early detection of pancreatic cancer. Chinese Journal Of Cancer Research 2015, 27: 321-31. PMID: 26361402, PMCID: PMC4560741, DOI: 10.3978/j.issn.1000-9604.2015.07.03.Peer-Reviewed Original ResearchPancreatic cancerPancreatic adenocarcinomaRisk factorsEarly detectionFourth common causeNew cancer casesGenetic risk factorsCancer deathCancer mortalityDefinitive curePrecursor lesionsCancer casesCommon causeWidespread screeningRisk-based strategyCancerNoninvasive methodGenetic mutationsMortal diseaseAdenocarcinomaCurrent standardDiseaseBest chanceClear needCauseA randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
Reiss K, Ahuja N, Baylin S, Mauro L, Linden S, White S, Laheru D, Herman J, Wolfgang C, Weiss M, Cameron J, Makary M, Azad N. A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. Journal Of Clinical Oncology 2015, 33: tps4144-tps4144. DOI: 10.1200/jco.2015.33.15_suppl.tps4144.Peer-Reviewed Original Research
2013
2564 resected periampullary adenocarcinomas at a single institution: trends over three decades
He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. Hepato Pancreato Biliary 2013, 16: 83-90. PMID: 23472829, PMCID: PMC3892319, DOI: 10.1111/hpb.12078.Peer-Reviewed Original ResearchConceptsPeriampullary adenocarcinomaBile ductSingle institutionPancreatic cancerIntraductal papillary mucinous neoplasmNumber of patientsPapillary mucinous neoplasmRelative survival ratesCurative intentWorse survivalLongterm outcomesMucinous neoplasmsSafe resectionLongterm survivalPathological diagnosisPrimary siteSurvival ratePancreaticoduodenectomyAdenocarcinomaPatientsSurvivalResectionSignificant differencesCancerDiagnosisDiscovery of early detection markers of pancreatic cancer and clinical application in blood-based screening
Kwak R, Keeley B, Guzzetta A, Jeschke J, Wolfgang C, Wang T, Herman J, Iacobuzio-Donahue C, Ahuja N. Discovery of early detection markers of pancreatic cancer and clinical application in blood-based screening. Pancreatology 2013, 13: e46. DOI: 10.1016/j.pan.2012.12.216.Peer-Reviewed Original ResearchIs It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm?
He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, Schulick RD, Hruban RH, Pawlik TM, Wolfgang CL. Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm? Journal Of The American College Of Surgeons 2013, 216: 657-665. PMID: 23395158, PMCID: PMC3963007, DOI: 10.1016/j.jamcollsurg.2012.12.026.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmNoninvasive intraductal papillary mucinous neoplasmsPapillary mucinous neoplasmPancreatic cancerFamily historyMucinous neoplasmsNegative marginsInitial operationPancreatic intraductal papillary mucinous neoplasmsPartial pancreatic resectionMetastatic pancreatic adenocarcinomaInvasive pancreatic cancerRisk of developmentDegree of dysplasiaInitial surgeryMargin statusPancreatic resectionClose surveillanceInvasive adenocarcinomaPancreatic adenocarcinomaResectionPatientsCancerSurgeryAdenocarcinoma
2009
Variations in Referral Patterns to High-Volume Centers for Pancreatic Cancer
Chang DC, Zhang Y, Mukherjee D, Wolfgang CL, Schulick RD, Cameron JL, Ahuja N. Variations in Referral Patterns to High-Volume Centers for Pancreatic Cancer. Journal Of The American College Of Surgeons 2009, 209: 720-726. PMID: 19959040, PMCID: PMC4036485, DOI: 10.1016/j.jamcollsurg.2009.09.011.Peer-Reviewed Original ResearchConceptsHigh-volume centersHigh-volume hospitalsNationwide Inpatient SamplePancreatic cancer patientsArea Resource FilePancreatic resectionCancer patientsInpatient SamplePancreatic cancerRadiation oncologistsCharlson Comorbidity Index scoreComorbidity Index scoreOdds of referralPrimary outcome variableResource FileCommunity poverty levelCalendar yearPatient ageOverall referralsReferral patternsVolume centersInsurance statusPrimary diagnosisInclusion criteriaRetrospective analysis